Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Interferon Treatment Eradicates a New Human Coronavirus in a Culture Model

By BiotechDaily International staff writers
Posted on 06 Mar 2013
A recently recognized human coronavirus was treated successfully in an in vitro model based on human bronchial epithelial tissue, which reduces fears that the virus might be capable of setting off a worldwide respiratory disease pandemic.

The recent emergence of a novel human coronavirus (HCoV-EMC) in the Middle East raised considerable concerns, as it was found to be associated with severe acute pneumonia, renal failure, and fatal outcome and thus resembled the clinical presentation of severe acute respiratory syndrome (SARS) observed in 2002 and 2003. Like SARS-CoV, HCoV-EMC is of zoonotic origin and closely related to bat coronaviruses.

To get a handle on this potentially fatal pathogen, investigators at Kantonal Hospital (St. Gallen, Switzerland) developed an in vitro model based on human bronchial epithelial cells, which are highly susceptible to HCoV-EMC infection and in which the virus is able to multiply at a faster initial rate than the SARS virus. The investigators employed advanced genomic research tools such as reverse transcription (RT)-PCR and RNAseq data to experimentally determine the identity of seven HCoV-EMC subgenomic mRNAs.

Results published in the February 19, 2013, online edition of the journal mBio revealed that while the human bronchial epithelial cells were readily responsive to type I and type III interferon (IFN), neither a pronounced inflammatory cytokine nor any detectable IFN responses were found following HCoV-EMC infection, suggesting that innate immune evasion mechanisms and possible IFN antagonists of the virus were operational in the human host. On the other hand, type I and type III IFN were found to efficiently reduce HCoV-EMC replication in the human cell cultures, providing a possible treatment option in cases of suspected HCoV-EMC infection.

"Surprisingly, this coronavirus grows very efficiently on human epithelial cells," said senior author Dr. Volker Thiel, a senior research fellow at Kantonal Hospital. "The other thing we found is that the viruses (HCoV-EMC, SARS, and the common cold virus) are all similar in terms of host responses: they do not provoke a huge innate immune response. We do not know whether the cases we observe are the tip of the iceberg, or whether many more people are infected without showing severe symptoms."

Related Links:
Kantonal Hospital



Channels

Genomics/Proteomics

view channel
Image: The bone marrow of mice with normal ether lipid production (top) contains more white blood cells than are found in the bone marrow of mice with ether lipid deficiency (bottom) (Photo courtesy of Washington University School of Medicine).

Inactivating Fatty Acid Synthase Reduces Inflammation by Interfering with Neutrophil Membrane Function

The enzyme fatty acid synthase (FAS) was shown to regulate inflammation by sustaining neutrophil viability through modulation of membrane phospholipid composition. Neutrophils are the most abundant... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more

Business

view channel

Biotech Acquisition Designed to Accelerate the Development and Marketing of Immunosequencing Applications

Adaptive Biotechnologies Corp. (Seattle, WA, USA), a developer of next-generation sequencing (NGS) to profile T-cell and B-cell receptors, has acquired of Sequenta, Inc. (South San Francisco, CA, USA), which is expected to expedite and expand the use of innovative immunosequencing technology for researchers and clinicians... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.